Study of Ketamine as an Antidepressant in Major Depressive Disorder

Primary Outcome Measures:

Evaluate the changes in neuroimaging and biochemistry measures with ketamine treatment.

Secondary Outcome Measures:

Evaluate the effects of ketamine on depression symptoms, manic symptoms, global change in psychiatric symptoms, and suicidal ideation.

Topic Depression Suicidality
Compound Ketamine
Country China
Visit trial
Status Unknown status
Results Published No
Start date 02 January 2012
End date 02 January 2013
Phase Phase I Phase II
Design Open
Type Interventional
Generation First
Participants 35
Sex All
Age 18- 65
Therapy No

Trial Details

Primary Outcome Measures: Evaluate the changes in neuroimaging and biochemistry measures with ketamine treatment. Secondary Outcome Measures: Evaluate the effects of ketamine on depression symptoms, manic symptoms, global change in psychiatric symptoms, and suicidal ideation.

Trial Number NCT01573741

Sponsors & Collaborators

Jinling Hospital
This company doesn't have a full profile yet, it is linked to a clinical trial.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.